Although continued efforts are being made to develop potent FLT3 tyrosine kinase inhibitors (TKIs), FLT3-ITD mutations are still associated with a dismal prognosis in AML.5 Thus, a number of combination therapies are being explored. The gene discussed is FLT3; the disease is acute myeloid leukemia.